With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55687-34-8,6-Bromoquinoxalin-2(1H)-one,as a common compound, the synthetic route is as follows.
To a stirred solution of the compound obtained from Preparation 29 (2 g, 8.89 mmol) in phosphorus oxychloride (15 mL), was added DMF (1 mL). The mixture was stirred at 120C for 1.5 hours then allowed to cool to room temperature. The dark solution was concentrated in vacuo and cautiously quenched with crushed ice. The aqueous suspension was neutralised with 10% potassium carbonate solution and extracted with DCM (2 x 30 mL). The combined organic phases were dried (Na2SO4), filtered and concentrated to give 1.94 g of the title compound as a brown solid.1H-NMR (400 MHz, DMSOd6): delta= 9.02(1 H, s), 8.40(1 H, d), 8.06(1 H, dd), 7.98(1 H, d). LCMS (run time = 2min): R4 = 1.69 min; m/z 243; 245 [M+H]+, 55687-34-8
As the paragraph descriping shows that 55687-34-8 is playing an increasingly important role.
Reference£º
Patent; PFIZER LIMITED; MILBANK, Jared Bruce John; PRYDE, David Cameron; TRAN, Thien Duc; WO2011/4276; (2011); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider